TL;DR: ARA-290 (Cibinetide) is an investigational peptide designed to activate the innate repair receptor (IRR) without triggering red blood cell production. It shows targeted efficacy for neuropathic pain, specifically sarcoidosis-associated small fiber neuropathy. Evidence Grade: B+ (Supported by multiple Phase 2 human clinical trials).
Chronic nerve pain rarely responds to standard anti-inflammatories. Patients with conditions like sarcoidosis often cycle through gabapentinoids and corticosteroids with minimal relief and heavy side effects.
Here is the thing: researchers have known for decades that erythropoietin (EPO) promotes tissue repair and protects nerves. But you cannot give patients long-term EPO without dangerously thickening their blood.
Enter ARA-290. Also known as Cibinetide, this 11-amino acid peptide isolates the tissue-healing properties of EPO while stripping away the blood-boosting risks. By targeting a specific cellular pathway called the innate repair receptor (IRR), ARA-290 is currently navigating clinical trials as a targeted therapy for small fiber neuropathy and chronic inflammation.
What Is ARA-290 (Cibinetide)?
ARA-290 is a synthetic, non-hematopoietic peptide. It was originally developed by Araim Pharmaceuticals to harness the neuroprotective benefits of EPO without the cardiovascular risks.
EPO binds to a classic receptor to produce red blood cells. However, during times of cellular stress, EPO also binds to a secondary receptor complex—the innate repair receptor (IRR).
ARA-290 is engineered to bind only to the IRR. When it attaches to this receptor, it triggers a cascade of anti-inflammatory and tissue-repair mechanisms.
The result? It halts the production of pro-inflammatory cytokines like TNF-alpha and promotes the survival and regrowth of damaged nerve fibers. Because it does not interact with the classic EPO receptor, it does not alter hematocrit levels or blood pressure.
Evidence-Based ARA-290 Benefits
The clinical data for ARA-290 is heavily anchored in human trials. This elevates its evidence grade above many widely discussed research peptides.
Neuropathic Pain and Sarcoidosis (Grade: B+)
Sarcoidosis is an inflammatory disease that frequently causes small fiber neuropathy (SFN). This leads to severe, burning neuropathic pain. ARA-290 was granted Orphan Drug Designation by the FDA specifically for this condition.
In a pivotal Phase 2b randomized controlled trial (NCT02039687), patients receiving ARA-290 experienced significant improvements in pain scores. Researchers also observed a physical increase in corneal nerve fiber density.
This physical regrowth of nerve fibers is critical. It suggests ARA-290 does not just mask pain signals; it actively repairs the damaged small nerve fibers causing the pain.
Metabolic and Inflammatory Conditions (Grade: C+)
Beyond sarcoidosis, IRR activation shows promise for broader metabolic stress. Animal models demonstrate that ARA-290 can reduce neuroinflammation associated with diabetic neuropathy.
In a study of patients with Type 2 diabetes (NCT01933525), ARA-290 administration improved HbA1c levels and reduced cholesterol. While these metabolic benefits are secondary to its neuroprotective effects, they highlight the peptide's systemic anti-inflammatory capacity.
Cibinetide Dosage Protocols & Administration
Note: The following reflects commonly reported research protocols and parameters from Cibinetide clinical trials. It is not a medical recommendation.
Because ARA-290 is a systemic peptide targeting nerve repair, clinical trials have relied heavily on daily subcutaneous injections.
Commonly Reported Research Protocol:
- Dose: 4 mg per day.
- Route: Subcutaneous (SQ) injection.
- Frequency: Once daily.
- Cycle Length: 28 days, followed by a clinical reassessment.
In the Phase 2b sarcoidosis trials, researchers utilized a 4 mg daily dose over a 28-day period. Some experimental protocols scale the dose down to 2 mg daily for milder inflammatory research. However, the 4 mg threshold showed the most robust nerve regeneration data.
Reconstitution requires bacteriostatic water. Due to its molecular structure, ARA-290 should be stored in a refrigerator (36°F to 46°F) immediately after reconstitution to prevent rapid degradation.
ARA-290 Safety Profile and Potential Side Effects
One of the primary drivers behind ARA-290's development was safety. By decoupling tissue repair from red blood cell production, researchers eliminated the severe clotting risks associated with traditional EPO therapy.
But there is a catch. No peptide is entirely without potential adverse effects.
Known Side Effects:
- Injection site reactions: Mild redness, itching, or swelling at the subcutaneous injection site.
- Headaches: Transient headaches were reported by a small percentage of clinical trial participants.
- Fatigue: Mild lethargy during the first week of administration.
Safety Advantages: Unlike traditional pain management drugs, ARA-290 does not cause cognitive impairment or dependency. Trial data confirms it does not elevate hemoglobin or hematocrit levels, avoiding the cardiovascular dangers of EPO.
There are currently no widely documented severe drug interactions. However, its immunomodulatory effects mean researchers should evaluate it carefully alongside immunosuppressants.
ARA-290 FDA Approval Status 2026
As of 2026, ARA-290 (Cibinetide) remains an investigational drug. It does not have full FDA approval for clinical prescription use in the general population.
However, its regulatory path is highly structured. The FDA granted Cibinetide Orphan Drug Designation for the treatment of sarcoidosis-associated small fiber neuropathy. This designation provides development incentives for drugs targeting rare diseases.
Current Regulatory Status:
- FDA Status: Investigational New Drug (IND).
- Compounding Eligibility: It is not currently listed as an FDA Category 1 or 2 compounding peptide. This means it cannot be legally compounded by 503A or 503B pharmacies for general prescription use.
- Availability: Restricted to approved clinical trials and strictly regulated research chemical suppliers.
If Phase 3 trials successfully replicate the nerve-regrowth data seen in Phase 2b, Cibinetide could see targeted FDA approval before the end of the decade. Until then, its legal status mirrors other strictly investigational compounds. You can review how state-level regulations impact access in our state-by-state peptide legality guide.
How ARA-290 Compares to Other Peptides
When researching peptides for pain and tissue repair, ARA-290 occupies a unique niche. Most healing peptides target muscle, tendon, or general gut inflammation, such as BPC-157 for gut health.
Here is how ARA-290 stacks up against other recovery compounds:
| Peptide | Primary Mechanism | Best Used For | Evidence Grade |
|---|---|---|---|
| ARA-290 | Innate Repair Receptor (IRR) agonist | Nerve repair, small fiber neuropathy | B+ |
| BPC-157 | Angiogenesis, nitric oxide pathway | Tendon repair, gastric healing | B |
| TB-500 | Actin upregulation | Muscle recovery, acute injury | B- |
While compounds like BPC-157 and TB-500 excel at musculoskeletal repair, they lack the targeted clinical data for nerve regeneration. ARA-290 is specifically engineered for the nervous system.
If the goal is mitigating metabolic stress, researchers often look toward mitochondrial peptides. For example, comparing the metabolic effects of 5-Amino-1MQ vs SS-31 highlights how different pathways address cellular fatigue. ARA-290, conversely, strictly targets the IRR for neuroprotection.
Bottom Line
ARA-290 (Cibinetide) represents a precise, evidence-backed approach to ARA-290 neuropathic pain management. By isolating the healing properties of EPO, it offers a pathway to repair damaged nerve fibers without dangerous cardiovascular side effects.
Quick Takeaways:
- It actively promotes the physical regrowth of small nerve fibers.
- Clinical trials show significant pain reduction in patients with sarcoidosis.
- The standard research dose is 4 mg daily via subcutaneous injection.
- It remains an investigational drug with Orphan Drug Designation, not yet FDA-approved for general use.
As clinical trials progress, ARA-290 may eventually transition from an investigational peptide to a frontline treatment for small fiber neuropathy.
This content is for educational purposes only and is not medical advice. Consult a healthcare professional before starting any peptide protocol.